[ad_1]
NEW YORK, March 3, 2021 / PRNewswire / –
WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of buyers of securities of Aquestive Therapeutics, Inc. (NASDAQ: AQST) between December 2, 2019 and September 25, 2020, inclusive (the “Class Period”). A class action has already been filed. If you want to act as the principal applicant, you must move the court not later than April 30, 2021.
SO WHAT: If you purchased Aquestive securities during the Class Period, you may be entitled to compensation without payment of any fees or out of pocket expenses through a contingency fee arrangement.
WHAT TO DO NEXT: To join the Aquestive class action lawsuit, go to http://www.rosenlegal.com/cases-register-2047.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information on the class action. A class action has already been filed. If you wish to act as the principal applicant, you must move the court not later than April 30, 2021. A principal plaintiff is a representative party acting on behalf of the other members of the group in the direction of the litigation.
WHY THE ROSEN LAW: We encourage investors to select qualified lawyers with a proven track record in leadership roles. Often, companies that issue opinions do not have comparable experience or resources. Rosen law firm represents investors around the world, focusing its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm completed the largest securities class action settlement against a Chinese company. Rosen law firm was ranked # 1 by ISS Securities Class Action Services for the number of securities class action settlements in 2017. The firm has been ranked in the top 3 every year since 2013 and has recovered hundreds of million dollars for investors. In 2019 alone, the company obtained $ 438 million for investors. In 2020 founding partner Laurence Rosen was appointed by law360 as titan of the Plaintiffs Bar. Many of the firm’s lawyers have been recognized by Lawdragon and Super Lawyers.
CASE DETAILS: According to the lawsuit, the defendants throughout the Class Period made false and / or misleading statements and / or failed to disclose that: (1) the data included in the film Libervant Buccal for the management of clusters of foreclosures (“Libervant”) New Drug Application (“NDA”) showed lower than desired level of drug exposure for certain weight groups; (2) the above significantly reduced the prospects for approval of the Libervant NDA; (3) therefore, it was foreseeable that the United States Food and Drug Administration (“FDA”) would not approve Libervant NDA in its current form; and (4) therefore, the company’s public statements were materially false and misleading at all material times. When the real details entered the market, the lawsuit claims that investors have suffered damage.
To join the Aquestive class action lawsuit, go to http://www.rosenlegal.com/cases-register-2047.html or call Phillip Kim, Esq. toll free at 866-767-3653 or by email [email protected] or [email protected] for information on the class action.
No class has been certified. Until a group is accredited, you are not represented by a lawyer, unless you retain one. You can choose the board of your choice. You can also remain an absent student and do nothing at this point. The ability of an investor to participate in a possible future recovery does not depend on its role as lead applicant.
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.
Lawyer advertising. Previous results do not guarantee a similar result.
Contact information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Rosen Law Firm, PA
275 Madison Avenue, 40th Floor
New York, NY 10016
Phone: (212) 686-1060
Toll free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
SOURCE Rosen Law Firm, PA
Related links
www.rosenlegal.com
[ad_2]
Source link
